Anti-PD-1 Antibody Combined With Peg-Asparaginase and Chidamide for the Early Stage of NK/T Cell Lymphoma
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
This prospective pilot study to evaluate the efficacy and safety of the anti-PD-1 antibody
combine with Peg-asparaginase and Chidamide regimen for stage IE and IIE ENKTL.